HTHitoe Torisu-Itakura

Hitoe Torisu-Itakura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hitoe Torisu-Itakura has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Norito Katoh

    Department of Dermatology, Kyoto Prefectural University of Medicine , Kyoto

    3 shared publications
  • Yoji Morisaki

    Eli Lilly Japan K.K. , Kobe

    3 shared publications
  • Akimichi Morita

    Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

    2 shared publications
  • Akio Tanaka

    Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima

    2 shared publications
  • Atsushi Nishikawa

    Eli Lilly Japan K.K., Kobe, Japan

    2 shared publications
  • Chie Yamamoto

    Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. Kobe Japan

    2 shared publications

Latest Publications

  • Open Access

    Classification of Itch Patterns and Sentiment Analysis in Patients With Atopic Dermatitis: Clustering Analysis of Patient‐Reported Data

    by Atsushi Otsuka, Taki Koda, Hideaki Kagitani, Takashi Matsuo, Junichi Danjo, Hitoe Torisu‐Itakura, Yasuhiro Miki, Satoshi Osaga

    Atopic dermatitis (AD), a prevalent inflammatory skin disease, significantly impairs quality of life. Pruritus manifests variably, complicating its classification and management. This study analyzed real‐world, self‐reported data from Atopiyo, Japan's largest AD smartphone application (October 2021–October 2024), to explore itch patterns, treatment behaviors, and patient sentiments. Data from 98 users with ≥ 6‐months of itch scores and ≥ 11‐months of posting history (73.5% female; 82.7% aged 18–50 years) were assessed. The mean itch score (0–5 scale) was 1.80, with a median of 47 posts/user and itch score posts peaked during spring and autumn transitions. The face (56.7 posts per patient) was the most frequently affected area. Cluster analysis grouped users into four categories based on patient‐reported itch metrics (minimum, maximum, median, and itch score variability): mild (Cluster 1, n = 38), moderate (Cluster 2, n = 27), high‐variability (Cluster 3, n = 16), and severe (Cluster 4, n = 17). Cluster 4 reported numerically lower prescribed medication use (35.3% vs. 57.9%–68.8% in other clusters). Symptom‐related keywords most commonly included “itch,” followed by “inflammation” and “pain”. Treatment‐related keywords frequently included “topical corticosteroids” and “prescription moisturizers”. Topic modeling identified six major themes, with symptoms and treatment concerns emerging prominently. The themes were: daily symptom management, symptoms and triggers, symptom impact on daily life, advanced treatment options, topical therapies, and symptom control. Topic‐“symptom control” was most prominent in the mild itch cluster, while Topic‐“symptom impact on daily life” was especially notable in the high‐variability itch cluster. In the moderate and severe itch clusters “symptoms and triggers” and “symptom impact on daily life” emerged as the leading topics. Sentiment analysis revealed a predominance of negative‐tone posts (46.3%) compared with positive (21.7%) or neutral (32.0%) posts across clusters. Overall, this study used real‐world smartphone data to reveal changing patients' needs and itch patterns in AD. Beyond symptom monitoring, these insights reveal potential gaps in treatment adherence and patients' emotional well‐being improvement, underscoring the need for personalized, patient‐centered care strategies.

  • Open Access

    Real‐World Treatment Patterns and Characteristics of Patients Aged 15 Years and Older Treated With Baricitinib for Alopecia Areata in Japan

    by Kazutoshi Harada, Taisuke Kojima, Yasuhiro Miki, Yoshitaka Isaka, Yumiko Nishikawa, Hitoe Torisu-Itakura, Manabu Ohyama

    Objective: This study aimed to describe real‐world treatment patterns and clinical characteristics of Japanese patients with alopecia areata (AA), particularly focusing on those treated with baricitinib. Methods: This retrospective observational study involved patients (aged ≥ 15 years) with a confirmed diagnosis of AA between January 1, 2018, and September 30, 2023. Patient demographics, hospital characteristics, comorbidities, and treatment patterns as described in a Japanese claims database were analyzed for overall and severe AA subtypes. Baricitinib users were assessed for treatment patterns, dose modifications, persistence, and the use of combination therapies. Results: Among 81,555 patients with AA included, 421 (0.52%) received baricitinib. The mean age was 40.7 years, with a higher proportion of females (58.91%). Most AA cases were diagnosed in clinics. Severe AA patients showed similar age and gender distributions. Comorbidities such as allergic rhinitis (34.01%) and atopic dermatitis (18.69%) were more prevalent among overall AA population. Topical corticosteroids (85.78%) and oral antihistamines (78.42%) were the most commonly used treatment. Intravenous corticosteroid pulse therapy (29.98%) and baricitinib (7.55%) were more frequently adopted for patients with severe AA than in the overall AA population (2.20% and 0.52%, respectively). Baricitinib users ( n = 403) were more often diagnosed in hospitals, especially university hospitals, than in clinics. Treatment was initiated predominantly at a 4‐mg dose (84.86%). Among 403 baricitinib users, treatment persistence at 3 and 9 months was 85.70% and 70.90%, respectively; combination therapy with topical corticosteroids (43.92%) and oral antihistamines (36.97%) was the most common treatment, while 34.49% received monotherapy with baricitinib. Atopic dermatitis (64.27%) and allergic rhinitis (32.75%) were frequent comorbidities among baricitinib users. Conclusion: Topical corticosteroids remain the common treatment for AA in Japan. High treatment persistence was observed with baricitinib and was occasionally used in combination with other therapies. These findings highlight evolving treatment trends and the distinct clinical profile of patients with AA treated with baricitinib in Japan.

  • Open Access

    Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance

    by Hideshi Torii, Akimichi Morita, Chie Yamamoto, Jiayi Dong, Mika Tsujimoto, Takashi Matsuo, Hitoe Torisu‐Itakura, Mamitaro Ohtsuki, Hidehisa Saeki

    We report findings from a post‐marketing study conducted from November 2016 to September 2022, which evaluated the safety and effectiveness of ixekizumab in Japanese patients with psoriasis under routine clinical practice for up to 52 weeks, and the incidence of serious infections and malignancies for up to 3 years. Of 804 patients in this analysis (67.9% male; median age, 54 years; mean disease duration, 11.8 years), 72.9%, 37.7%, 7.8%, and 3.7% had psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis, respectively (subtypes not mutually exclusive). At 52 weeks, adverse events were reported in 203 patients (25.3%). Serious adverse events were reported in 36 patients (4.5%), including serious infections and infestations ( n = 13, 1.6%). The incidence of serious infections and benign, malignant, and unspecified neoplasms was 0.8% ( n = 5) and 0.6% ( n = 4) respectively, at 3 years. Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from week 12); 550 patients (68.4%) received Q2/Q4 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from weeks 2 to 12 and 80 mg every 4 weeks thereafter); and 117 patients (14.6%) discontinued before week 12 or received only one dose after week 12. A higher proportion of patients in the Q2/Q2 group had psoriatic arthritis (56.9% [ n = 78]) compared with the Q2/Q4 group (32.9% [ n = 181]). Among patients in the Q2/Q2 versus the Q2/Q4 dose groups, 21 (15.3%) and 141 (25.6%) respectively had adverse events and 2 (1.5%) and 32 (5.8%) respectively had serious adverse events. The mean Psoriasis Area and Severity Index score and body surface area percentage significantly decreased from baseline to week 52 for all psoriasis subtypes and by Q2/Q2 and Q2/Q4 ixekizumab doses ( p < 0.01 or p < 0.001). Overall, the safety and effectiveness of ixekizumab in real‐world settings in Japan were similar to those reported in clinical trials.


  • Open Access

    Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)

    by Norito Katoh, Akio Tanaka, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Chie Yamamoto, Ken Igawa

    Background: Moderate-to-severe atopic dermatitis (AD) affects the quality of life of patients. More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to interleukin-13, a key mediator in AD pathogenesis. In Japanese patients, lebrikizumab has been evaluated through week 16 in the randomized placebo-controlled phase III ADhere-J study. Objectives: To evaluate the long-term efficacy and safety of lebrikizumab in combination with topical corticosteroids (TCS) in the ADhere-J study. Methods: Patients aged ≥12 years weighing ≥ 40 kg with moderate-to-severe AD and receiving either subcutaneous lebrikizumab 250 mg ­every 2 weeks (Q2W)/every 4 weeks (Q4W) or placebo during the 16-week induction period were evaluated during the long-term maintenance period from week 16 to week 68. Responders achieved the co-primary endpoints at week 16: an Investigator’s Global Assessment score of 0 or 1 [IGA (0,1)] with ≥ 2-point improvement from baseline and/or ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75). In this analysis, week 16 responders received lebrikizumab 250 mg Q2W or Q4W combined with TCS during the maintenance period (maintenance primary population; MPP); week 16 per-protocol nonresponders received lebrikizumab Q2W with TCS (maintenance escape population; MEP). Major endpoints included IGA (0,1) with ≥ 2-point improvement from baseline and EASI 75 through week 68. Other outcomes included quality of life, itch and serum thymus and activation-regulated chemokine. The trial was registered with ClinicalTrials.gov (NCT04760314). Results: At week 68, 66–81% of 103 patients in the MPP and 32–38% of 168 patients in the MEP achieved IGA (0,1) with ≥ 2-point improvement from baseline. EASI 75 was maintained by 83–89% of patients in the MPP, while 71–80% of patients in the MEP achieved this outcome by week 68. Across treatment arms, patients in the MPP tended to maintain improvements recorded at week 16, while patients in the MEP steadily improved across the maintenance period. No new safety signals were reported, and most treatment-emergent adverse events were mild or moderate in severity in both populations. Safety outcomes were consistent with previous reports for lebrikizumab treatment in global studies. Conclusions: These results support the use of lebrikizumab in combination with TCS for the treatment of moderate-to-severe AD in the Japanese population in the long term.


  • Open Access

    Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis

    by Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh

    Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low- to mid-potency topical corticosteroids on patient-reported outcomes at 16 weeks in Japanese patients with moderate-to-severe atopic dermatitis is evaluated. Eligible patients (n = 286) were randomized 2:2:3 to receive placebo+ topical corticosteroids, 250 mg lebrikizumab every 4 weeks (LEBQ4W+topical corticosteroids, 500 mg loading dose at baseline), or 250 mg lebrikizumab every 2 weeks (LEBQ2W+ topical corticosteroids, 500 mg loading dose at baseline and Week 2) by subcutaneous injection. All PRO endpoints for the study were met; patients in the lebrikizumab in combination with topical corticosteroids groups demonstrated statistically significant and clinically meaningful improvements compared with placebo in combination with topical corticosteroids in Skin Pain NRS, DLQI, POEM, WPAI-AD, and SCORAD scales. Lebrikizumab combined with topical corticosteroids compared with placebo+topical corticosteroids improved patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis.


  • Open Access

    Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials

    by Norito Katoh, Yasushi Takita, Yoshitaka Isaka, Atsushi Nishikawa, Hitoe Torisu-Itakura, Hidehisa Saeki

    Introduction Baricitinib is an oral selective Janus kinase (JAK)1/JAK2 inhibitor approved in Japan and the European Union for the treatment of atopic dermatitis (AD). The aim of this study is to report pooled safety data for baricitinib in the Japanese subpopulation of the clinical development program in moderate-to-severe AD. Methods This analysis included participant-level safety data from five double-blind, randomized clinical studies and one double-blind, randomized, long-term extension study, reported in three datasets for the Japanese subpopulation: (1) placebo-controlled, (2) baricitinib 2 mg and 4 mg extended (“2-mg—4-mg extended”), and (3) all baricitinib doses (“All-bari-AD”). The data cutoff was 13 December 2019. Safety outcomes included treatment-emergent adverse events, adverse events of special interest, and abnormal laboratory changes. Proportions of participants with events and incidence rates were calculated. Results Data were collected for 341 participants from Japan who received baricitinib for 371.7 participant-years (median duration 371.0 days). In the placebo-controlled dataset, the frequencies of serious infections and herpes zoster were low and similar between treatment groups, and the incidence of treatment-emergent infections, in particular herpes simplex, was higher in the baricitinib groups compared with the placebo group. No gastrointestinal perforations, tuberculosis, positively adjudicated cardiovascular events, deep vein thrombosis, or pulmonary embolism were reported with exposure up to 2 years in the All-bari-AD dataset. There were no deaths in the Japanese subpopulation. Conclusions This integrated safety analysis in the subpopulation of Japanese participants is consistent with the established safety profile of baricitinib in the global study population with moderate-to-severe AD. Clinicaltrials.gov identifiers NCT02576938, NCT03334396, NCT03334422, NCT03428100, NCT03733301, and NCT03334435.


  • Open Access

    Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients

    by Hitoe Torisu-Itakura, Peter Anderson, James Piercy, James Pike, Atsushi Sakamoto, Kenji Kabashima

    Patients with atopic dermatitis experience a broad range of symptoms, including both itch and skin pain, however it is not clear how these symptoms combine to impact patients in everyday life. This survey of 56 dermatologists and 265 patients with a history of moderate or severe atopic dermatitis investigated the impact of both itch and skin pain on quality of life and treatment satisfaction in Japan. Patients were categorised into three groups depending on the presence of these symptoms; patients with either no itch or skin pain, patients with itch but no skin pain, or patients with both itch and skin pain. These three groups were then compared. Patients with both itch and skin pain reported this combination of symptoms together impacted on their daily lives more than patients with itch but no skin pain, or no itch or skin pain. In particular, patients with both itch and skin pain had more areas of their body affected and reported being more bothered by their symptoms compared to those who did not experience these symptoms, with daily work impairment, sleep disruption and quality of life all worse. Importantly, patients with both itch and skin pain were more likely to be dissatisfied with the lack of improvement in their condition and with the convenience of their treatment. These results suggest that physicians should take into consideration the presence of both itch and skin pain when making treatment decisions in atopic dermatitis, and the need to consider treatments to target both symptoms.


  • Open Access

    Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis

    by Akimichi Morita, Yukari Okubo, Yoji Morisaki, Hitoe Torisu-Itakura, Yoshinori Umezawa

    Introduction In 2018, ixekizumab (80 mg every 2 weeks [Q2W] beyond Week 12) received approval in Japan for patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). This open-label study evaluated the efficacy and safety of ixekizumab (80 mg Q2W from Week 12 to Week 20) in Japanese patients with GPP and EP. Methods Seven patients with GPP and five patients with EP were enrolled. An initial dose of 160 mg (subcutaneous [SC] injection) was followed by 80 mg Q2W SC until Week 12. Primary endpoint assessed global improvement score (GIS) by comparing psoriatic findings, Static Physician Global Assessment, Psoriasis Area and Severity Index score, and other evaluations with those at the baseline and were graded as 1 = resolved, 2= improved, 3 = unchanged, and 4 = worsened. Patients who showed GIS = 1 (resolved) at Week 12 completed the study. Patients with GIS ≥ 2 continued to receive ixekizumab 80 mg Q2W until Week 20. Results At Week 12, four of seven patients with GPP showed “resolved,” two showed “improved,” and one showed “worsened.” Of five patients with EP, one showed “resolved” and four showed “improved.” Two patients with GPP and four patients with EP continued ixekizumab treatment until Week 20. At Week 20, one of the two patients with GPP showed “resolved” and one patient showed “improved.” All four patients with EP showed “improved.” One non-drug related serious adverse event was reported by one patient with EP at Week 12. From Week 12 to Week 20, no adverse events (AEs) were reported in patients with GPP, but two mild AEs were reported in one of the four patients with EP. Conclusions This study indicates that ixekizumab continuous Q2W dosing is efficacious and safe for patients with GPP and EP. Clinical Trial Registration NCT03942042.


  • Open Access

    Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

    by Yukari Okubo, Ann Chuo Tang, Sachie Inoue, Hitoe Torisu-Itakura, Mamitaro Ohtsuki

    Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians. Objective: This secondary analysis aimed to determine whether patient and physician users of biologics have higher treatment goals than users of non-biologics. Methods: A survey for both patients and physicians on background characteristics, disease severity, treatment goals, treatment satisfaction, and health-related quality of life was conducted at 54 sites. Association between treatment goals and biologic/non-biologic users was assessed using ordinal logistic regression models. Results: In total, 449 patient-physician pairs agreed to participate; 425 completed the survey and were analyzed. More biologic users than non-biologic users reported complete clearance (Psoriasis Area and Severity Index 100) as a treatment goal (patient-reported: 23.6% vs. 16.1%; physician-reported: 26.9% vs. 2.2%). Biologic users were significantly associated with higher treatment goals than non-biologic users (patient-reported: 1.8 (1.15–2.87) (odds ratio (9 5% CI)), p = 0.01; physician-reported: 11.0 (5.72–21.01), p < 0.01). Among biologic users, higher treatment goals were associated with higher treatment satisfaction (patient- and physician-rated); lower treatment goals were associated with back lesions and increasing patient age (patient-rated) and higher disease severity (physician-rated). Conclusion: Use of biologics among patients with psoriasis was associated with higher treatment goals. Further use of biologics contributed to treatment satisfaction. Appropriate treatment goals that are shared among patients and their physicians may improve treatment outcomes.


  • Open Access

    Evaluation of treatment satisfaction misalignment between Japanese psoriasis patients and their physicians – Japanese psoriasis patients and their physicians do not share the same treatment satisfaction levels

    by Yukari Okubo, Hitoe Torisu-Itakura, Takao Hanada, Toshihiko Aranishi, Sachie Inoue, Mamitaro Ohtsuki

    [OBJECTIVES] High treatment satisfaction in both patients and physicians is one of important factors to improve QOL in psoriasis patients. This study aimed to evaluate treatment satisfaction alignment between psoriasis patients and physicians and to identify factors associated with satisfaction misalignment, especially ‘physician-predominant’ misalignment. [METHODS] This is a nationwide multicenter cross-sectional study. Subjects were paired moderate to severe psoriasis outpatients and their physicians. Treatment satisfaction was evaluated by a scale from 0 to 10. Subjects were defined as ‘misaligned’ when the difference of treatment satisfaction was over +/- 1 between the patient-physician pair. [RESULTS] A total of 425 pairs were collected from 54 facilities in Japan. The mean patient age and disease duration were 56.5 years and 18.7 years, respectively. The mean physician age was 50.6 years and 69.6% of physicians specialized in psoriasis. Treatment satisfaction misalignment was found in 49.9% of the patient-physician pairs. Among misaligned pairs, 43.6% were ‘physician-predominant’ pairs. In the multivariate logistic regression analyses, ‘treatment is effective’ was the most important reason for treatment satisfaction (odds ratio (OR): 35.5; 95%confidence interval (CI): 5.43, 231.78). Symptoms in the genital area (OR: 10.2; 95%CI: 2.55, 40.93), and lack of understanding on treatment options by patients (OR: 7.5; 95%CI: 2.19, 25.94) were key factors leading to ‘physician-predominant’. [CONCLUSIONS] The results suggest that genital psoriasis plays an important role on treatment satisfaction from the patient perspective, and illustrate the importance of communication between patients and physicians which potentially resolves these factors and improve misalignment.